[grow_thumb image=”https://telecareaware.com/wp-content/uploads/2017/04/Entra.jpg” thumb_width=”150″ /]Entra is a London startup company developing a quick, home-based blood test for clinically valid blood counts. Targeted to the needs of chemotherapy patients, where blood counts are critical in their receiving and timing of treatments, the Affinity (photo left) is designed to take a small sample, analyze it, wirelessly send the information to the hospital or clinic, and enter into the patient’s EHR. It is currently being tested with The Royal Marsden Hospital, a leading UK cancer center, to validate its optical analytics and generate cost-effectiveness data. Blood counts are not only critical to correct patient treatment, but also to assigning and canceling appointments. Entra is being supported by £1.14 million in funding from Innovate UK, much of it through the Biomedical Catalyst. The timeline to commercial release is being estimated at two years. It’s anticipated that once verified, the blood count technology could be further developed for other uses. Gov.UK. Hat tip to our Eye on Tenders, Susanne Woodman
Raising funds for another type of blood testing is a NYC-based biotech company, Haystack, which is pioneering a single blood test for multiple cancers through proteome molecular profiling. Its goal is early detection of multiple cancers through one test using panels of biomarkers. The research team headed by John Wilson, PhD, who is affiliated with Cold Spring Harbor Laboratory, are ready first with pancreatic and lung cancer samples. This has gained the interest of pharma companies who are seeking a companion diagnostic for their drug trials. It was also a category winner at MedStartr’s #MedMo16 last December and presenter at #RISE2017 in March. Haystack’s MedStartr page. Video of Haystack’s presentation at #RISE2017 is on YouTube here (at 58:00) TTA is a MedStartr and Health 2.0 NYC supporter/media sponsor since 2010; event videos are available at Medstartr.tv.